Treato Launches Treato Pharma: Next Generation Patient Intelligence from Billions of Online Patient Discussions

Share Article

Aggregated real-life experiences give pharmaceutical marketers unprecedented access to the Patient Voice

News Image
Treato Pharma deserves a central place in every pharma marketer's toolkit.

Treato, the social health intelligence provider, today announced the launch of Treato Pharma, an innovative patient intelligence service that provides pharma marketers with real-time insights extracted from patient experiences posted on blogs and forums.

Developed using deep expertise in Natural Language Processing, medical terminology, and “Big Data” analytics, Treato has aggregated and analyzed over one billion online patient discussions to understand what patients are saying in their own words.

Treato Pharma leverages Treato's extensive dataset to answer the essential questions pharmaceutical marketers encounter in their daily work, and to enable them to adjust strategy and messages to actual patient behavior. The service provides drillable infographics and analytics that help pharmaceutical marketers tap into the minds of their end-customers – the patients – and hear their collective voices in an unprecedented way.

“Patient online discussions are rich with information that pharmaceutical marketers need, but until now it was never feasible to incorporate them into their marketing efforts on such a vast scale and in real time,” said Ido Hadari, president of Treato. “Treato Pharma distills the signal from the noise, revealing crucial points that go far beyond sentiment analysis. This is the most effective way to gain unmediated patient perceptions, bringing the patient voice into the pharma boardroom."

Treato Pharma complements existing social listening tools by adding an in-depth understanding of patients' health experiences, perceptions and attitudes. And unlike traditional market research methods, Treato's insights are based on millions of spontaneous, unsolicited patient conversations.

Extensive competitive analysis tools within Treato Pharma provide comparative patient perceptions and extract the topics discussed more and less often than competitors. This breakdown lets agencies and pharma marketers pinpoint messages that will resonate with their patients and differentiate them from the competitors. Treato Pharma's distinctive drug switching map visually summarizes the switching reasons and allows users to drill down into the specific social media posts that describe the switching activity.

"Treato Pharma enables pharma marketers to gain easy access to immediately actionable information that will improve the effectiveness of their marketing campaigns in a manner that is effective, compelling and innovative," said Mike Spitz, editor of the blog Pixels&Pills and managing director, healthcare and life sciences at Zemoga. "Treato Pharma deserves a central place in every pharma marketer's toolkit."

Treato executives will be demonstrating and discussing Treato Pharma in two panels at Health 2.0, taking place in San Francisco, October 7-10.

  • Gideon Mantel, Treato's CEO and Co-founder, will present at Clinical Trial Recruitment and Clinical Research Innovation, Sunday, Oct. 7, 4:00 - 5:00 pm, Franciscan CD (Pre-conference iPharma).
  • Ido Hadari, Treato's President, will present at Start Your Engines! Search and Content, Tuesday, Oct. 9, 3:30 pm, Imperial A

Pharmaceutical marketers and agencies that are interested in more information or a demo of Treato Pharma are invited to visit, or contact info (at) treato (dot) com.

About Treato
Treato is a new platform of patient intelligence based on online discussions about real life experiences. To date, over a billion patient discussions from forums and blogs have been analyzed, generating the collective patient voice for the very first time. The company is privately held and backed by Reed Elsevier Ventures and a group of private investors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michal Tamir
Email >
Follow us on
Visit website